Cue Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
Cue Biopharma has a total shareholder equity of $25.4M and total debt of $5.3M, which brings its debt-to-equity ratio to 20.9%. Its total assets and total liabilities are $44.8M and $19.4M respectively.
Key information
20.9%
Debt to equity ratio
US$5.29m
Debt
Interest coverage ratio | n/a |
Cash | US$32.42m |
Equity | US$25.37m |
Total liabilities | US$19.44m |
Total assets | US$44.81m |
Recent financial health updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Financial Position Analysis
Short Term Liabilities: CUE's short term assets ($37.3M) exceed its short term liabilities ($16.8M).
Long Term Liabilities: CUE's short term assets ($37.3M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: CUE has more cash than its total debt.
Reducing Debt: CUE's debt to equity ratio has increased from 0% to 20.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CUE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CUE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.1% each year
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 20:59 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cue Biopharma, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Madhu Kumar | Baird |
Brian Skorney | Baird |
Zhiqiang Shu | Berenberg |